Want to see TLSI full AI Analyst Report?
TLSI Stock Chart & Stats
$5.03
$0.10(2.37%)
At close: 4:00 PM EDT
$5.03
$0.10(2.37%)
Day’s Range― - ―
52-Week Range$2.20 - $7.95
Previous Close$4.32
Volume94.41K
Average Volume (3M)379.51K
Market Cap
$225.36M
Enterprise Value$253.39M
Total Cash (Recent Filing)$46.29M
Total Debt (Recent Filing)$34.43M
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Nov 10, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.30
Shares Outstanding61,574,600
10 Day Avg. Volume165,215
30 Day Avg. Volume379,515
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)-7.81
Price to Sales (P/S)5.86
P/FCF Ratio-13.97
Enterprise Value/Market Cap1.12
Enterprise Value/Revenue5.62
Enterprise Value/Gross Profit6.55
Enterprise Value/Ebitda-11.70
Forecast
1Y Price Target
$10.40Price Target Upside106.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.33
Revenue Forecast (FY)$53.12M
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth And Gross MarginsRapid revenue growth combined with consistently high gross margins indicates meaningful demand for the company’s offerings and favorable underlying product economics. If maintained, this combination can support operating leverage, provide resources for pipeline investment, and strengthen the commercial foundation over the next several quarters.
Proprietary Drug-delivery Platform And Oncology PipelineTriSalus combines a differentiated pressure-enabled delivery technology with an immuno-oncology pipeline focused on solid tumors, particularly liver cancer. This integrated platform may create multiple avenues for clinical and commercial expansion, while specialized technology can support differentiation in a difficult oncology market.
Expanded Device Portfolio Following FDA ClearanceFDA clearance adds a new device to the pressure-enabled drug-delivery portfolio and broadens use across complex embolization procedures. The planned market release could increase physician flexibility, extend access to distal vessels, and create a durable adoption pathway for the broader PEDD platform.
Bears Say
Persistent UnprofitabilityDeeply negative net, EBIT, and EBITDA margins show that revenue growth has not yet translated into sustainable earnings. Continued operating losses could delay self-funded expansion, require additional capital, and limit the company’s ability to convert its commercial and clinical progress into durable shareholder value.
Heavy Ongoing Cash BurnThe company continues to consume substantial cash in operations and investment despite improvement from earlier periods. Persistently negative free cash flow increases dependence on external financing and leaves less flexibility to fund clinical development, commercialization, or unexpected operating needs internally.
Stretched And Volatile Balance SheetHigh leverage relative to the equity base materially constrains financial flexibility, while prior periods of negative equity indicate accumulated losses and balance-sheet volatility. This structure can increase financing pressure and make it harder to sustain investment if operating losses and cash burn persist.
TriSalus Life Sciences News
TLSI FAQ
What was TriSalus Life Sciences’s price range in the past 12 months?
TriSalus Life Sciences lowest stock price was $2.20 and its highest was $7.95 in the past 12 months.
What is TriSalus Life Sciences’s market cap?
TriSalus Life Sciences’s market cap is $225.36M.
When is TriSalus Life Sciences’s upcoming earnings report date?
TriSalus Life Sciences’s upcoming earnings report date is Nov 10, 2026 which is in 18 days.
How were TriSalus Life Sciences’s earnings last quarter?
TriSalus Life Sciences released its earnings results on Aug 06, 2026. The company reported -$0.16 earnings per share for the quarter, missing the consensus estimate of -$0.155 by -$0.005.
Is TriSalus Life Sciences overvalued?
According to Wall Street analysts TriSalus Life Sciences’s price is currently Undervalued.
Does TriSalus Life Sciences pay dividends?
TriSalus Life Sciences does not currently pay dividends.
What is TriSalus Life Sciences’s EPS estimate?
TriSalus Life Sciences’s EPS estimate is -0.13.
How many shares outstanding does TriSalus Life Sciences have?
TriSalus Life Sciences has 61,574,600 shares outstanding.
What happened to TriSalus Life Sciences’s price movement after its last earnings report?
TriSalus Life Sciences reported an EPS of -$0.16 in its last earnings report, missing expectations of -$0.155. Following the earnings report the stock price went up 15.195%.
Which hedge fund is a major shareholder of TriSalus Life Sciences?
Currently, no hedge funds are holding shares in TLSI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TriSalus Life Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.40 (106.76% Upside)
$10.40 (106.76% Upside)
Blogger Sentiment
Bearish
TLSI Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 38.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 5.5%
Last 30 Days ▲ 17.2%
Last 30 Days ▲ 17.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.51%
12-Months-Change
Fundamentals
Return on Equity
273.71%
Trailing 12-Months
Asset Growth
51.14%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
TriSalus Life Sciences
TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors. Additionally, TriSalus is advancing SD-101, an investigational immunotherapeutic that incorporates pressure-enabled drug delivery technology. This experimental therapy is currently being explored for its application in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company's operations are headquartered in Westminster, Colorado.
TLSI Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized a major clinical and economic validation of PEDD (landmark real-world study, strong pipeline, meaningful early results in multiple new indications) and a deliberate commercial build intended to capture a large addressable market. Near-term financials were impacted by the deliberate salesforce expansion (temporary revenue disruption, higher operating losses) and a regulatory delay for TriNav Advance that defers some expected second-half revenue. Management positions the investments as strategic and funded by a solid cash balance, with expectations of sustained ramp and commercial momentum through the remainder of 2026 and beyond.View all TLSI earnings summariesTLSI Stock 12 Month Forecast
Average Price Target
$10.40
▲(106.76% Upside)
Technical Analysis
Ownership Overview
28.15% Insiders
6.62% Mutual Funds
0.15% Other Institutional Investors
58.35% Public Companies and
Individual Investors